189 related articles for article (PubMed ID: 22310229)
1. Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH.
Kirubakaran S; Gorla SK; Sharling L; Zhang M; Liu X; Ray SS; Macpherson IS; Striepen B; Hedstrom L; Cuny GD
Bioorg Med Chem Lett; 2012 Mar; 22(5):1985-8. PubMed ID: 22310229
[TBL] [Abstract][Full Text] [Related]
2. Phthalazinone inhibitors of inosine-5'-monophosphate dehydrogenase from Cryptosporidium parvum.
Johnson CR; Gorla SK; Kavitha M; Zhang M; Liu X; Striepen B; Mead JR; Cuny GD; Hedstrom L
Bioorg Med Chem Lett; 2013 Feb; 23(4):1004-7. PubMed ID: 23324406
[TBL] [Abstract][Full Text] [Related]
3. Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis.
Umejiego NN; Gollapalli D; Sharling L; Volftsun A; Lu J; Benjamin NN; Stroupe AH; Riera TV; Striepen B; Hedstrom L
Chem Biol; 2008 Jan; 15(1):70-7. PubMed ID: 18215774
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolic anilides as broad specificity inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors.
Lee S; Ku AF; Vippila MR; Wang Y; Zhang M; Wang X; Hedstrom L; Cuny GD
Bioorg Med Chem Lett; 2020 Dec; 30(24):127543. PubMed ID: 32931912
[TBL] [Abstract][Full Text] [Related]
5. Selective and potent urea inhibitors of cryptosporidium parvum inosine 5'-monophosphate dehydrogenase.
Gorla SK; Kavitha M; Zhang M; Liu X; Sharling L; Gollapalli DR; Striepen B; Hedstrom L; Cuny GD
J Med Chem; 2012 Sep; 55(17):7759-71. PubMed ID: 22950983
[TBL] [Abstract][Full Text] [Related]
6. Triazole inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase.
Maurya SK; Gollapalli DR; Kirubakaran S; Zhang M; Johnson CR; Benjamin NN; Hedstrom L; Cuny GD
J Med Chem; 2009 Aug; 52(15):4623-30. PubMed ID: 19624136
[TBL] [Abstract][Full Text] [Related]
7. Optimization of benzoxazole-based inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase.
Gorla SK; Kavitha M; Zhang M; Chin JE; Liu X; Striepen B; Makowska-Grzyska M; Kim Y; Joachimiak A; Hedstrom L; Cuny GD
J Med Chem; 2013 May; 56(10):4028-43. PubMed ID: 23668331
[TBL] [Abstract][Full Text] [Related]
8. The structural basis of Cryptosporidium -specific IMP dehydrogenase inhibitor selectivity.
Macpherson IS; Kirubakaran S; Gorla SK; Riera TV; D'Aquino JA; Zhang M; Cuny GD; Hedstrom L
J Am Chem Soc; 2010 Feb; 132(4):1230-1. PubMed ID: 20052976
[TBL] [Abstract][Full Text] [Related]
9. Novel adenosine-derived inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase.
Shigetomi K; Sarwono AEY; Ichikawa S; Ubukata M
J Antibiot (Tokyo); 2019 Dec; 72(12):934-942. PubMed ID: 31296916
[TBL] [Abstract][Full Text] [Related]
10. Binding mode of inhibitors and Cryptosporidium parvum IMP dehydrogenase: A combined ligand- and receptor-based study.
Li RJ; Wang YL; Wang QH; Huang WX; Wang J; Cheng MS
SAR QSAR Environ Res; 2015; 26(5):421-38. PubMed ID: 25978645
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, in vitro evaluation and cocrystal structure of 4-oxo-[1]benzopyrano[4,3-c]pyrazole Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase (CpIMPDH) inhibitors.
Sun Z; Khan J; Makowska-Grzyska M; Zhang M; Cho JH; Suebsuwong C; Vo P; Gollapalli DR; Kim Y; Joachimiak A; Hedstrom L; Cuny GD
J Med Chem; 2014 Dec; 57(24):10544-50. PubMed ID: 25474504
[TBL] [Abstract][Full Text] [Related]
12. Structure of Cryptosporidium IMP dehydrogenase bound to an inhibitor with in vivo antiparasitic activity.
Kim Y; Makowska-Grzyska M; Gorla SK; Gollapalli DR; Cuny GD; Joachimiak A; Hedstrom L
Acta Crystallogr F Struct Biol Commun; 2015 May; 71(Pt 5):531-8. PubMed ID: 25945705
[TBL] [Abstract][Full Text] [Related]
13. A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase.
Sharling L; Liu X; Gollapalli DR; Maurya SK; Hedstrom L; Striepen B
PLoS Negl Trop Dis; 2010 Aug; 4(8):e794. PubMed ID: 20706578
[TBL] [Abstract][Full Text] [Related]
14. Molecular Basis of P131 Cryptosporidial-IMPDH Selectivity-A Structural, Dynamical and Mechanistic Stance.
Omolabi KF; Agoni C; Olotu FA; Soliman MES
Cell Biochem Biophys; 2021 Mar; 79(1):11-24. PubMed ID: 33058015
[TBL] [Abstract][Full Text] [Related]
15. A probable means to an end: exploring P131 pharmacophoric scaffold to identify potential inhibitors of Cryptosporidium parvum inosine monophosphate dehydrogenase.
Omolabi KF; Iwuchukwu EA; Agoni C; Olotu FA; Soliman MES
J Mol Model; 2021 Jan; 27(2):35. PubMed ID: 33423140
[TBL] [Abstract][Full Text] [Related]
16. QSAR and deep learning model for virtual screening of potential inhibitors against Inosine 5' Monophosphate dehydrogenase (IMPDH) of Cryptosporidium parvum.
Asmare MM; Nitin N; Yun SI; Mahapatra RK
J Mol Graph Model; 2022 Mar; 111():108108. PubMed ID: 34911011
[TBL] [Abstract][Full Text] [Related]
17. Repurposing existing drugs: identification of irreversible IMPDH inhibitors by high-throughput screening.
Sarwono AEY; Mitsuhashi S; Kabir MHB; Shigetomi K; Okada T; Ohsaka F; Otsuguro S; Maenaka K; Igarashi M; Kato K; Ubukata M
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):171-178. PubMed ID: 30451014
[TBL] [Abstract][Full Text] [Related]
18. Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis.
Gorla SK; McNair NN; Yang G; Gao S; Hu M; Jala VR; Haribabu B; Striepen B; Cuny GD; Mead JR; Hedstrom L
Antimicrob Agents Chemother; 2014; 58(3):1603-14. PubMed ID: 24366728
[TBL] [Abstract][Full Text] [Related]
19. Cryptosporidium parvum IMP dehydrogenase: identification of functional, structural, and dynamic properties that can be exploited for drug design.
Umejiego NN; Li C; Riera T; Hedstrom L; Striepen B
J Biol Chem; 2004 Sep; 279(39):40320-7. PubMed ID: 15269207
[TBL] [Abstract][Full Text] [Related]
20. Structural determinants of inhibitor selectivity in prokaryotic IMP dehydrogenases.
Gollapalli DR; Macpherson IS; Liechti G; Gorla SK; Goldberg JB; Hedstrom L
Chem Biol; 2010 Oct; 17(10):1084-91. PubMed ID: 21035731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
